Compare Cassava Sciences Inc (FLNA) vs ON Holding AG (ONON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs ON Holding AG — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while ON Holding AG trades at $38.67 (market cap $12.49B). The key difference: ON Holding AG is far larger — about 235× Cassava Sciences Inc's market cap, and ON Holding AG is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | ONON | |
|---|---|---|
Market Cap | $53.14M | $12.49B |
Sector | Health | Technology |
52-Week High | $4.64 | $54.24 |
52-Week Low | $1.09 | $31.88 |
Enterprise Value | -$33.43M | $11.81B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.
The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.
ONON trades at $37.80, up 0.16% with neutral technical signals. The company shows strong fundamentals with Q1 2026 EPS beating expectations at $0.47 versus $0.34, revenue of $3.01B in 2025, and improving margins. Analyst sentiment is bullish with 77% buy ratings and a $47.33 consensus price target, suggesting 25% upside. Recent news highlights innovation and expansion into luxury lifestyle markets.
Outlook remains positive driven by earnings momentum and margin expansion, but risks include premium valuation and competitive pressures. The stock offers growth potential if execution continues, though high P/E of 40.42 requires sustained profit growth to justify current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About ON Holding AG
ON Holding AG is a Swiss sports company primarily known for its high-performance running shoes, apparel, and accessories under the 'On' brand. The company emphasizes a blend of high-end design, proprietary cloud technology (like CloudTec cushioning), and sustainability in its products. On has rapidly gained market share globally, appealing to both competitive athletes and general consumers in the performance and lifestyle footwear segments.
Read more on ONON →
